AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24180554 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyp Specific Polymer analysis
Number of subjects: 0
Study 24180554 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy and histology examination
Number of subjects: 0
Study 20624152 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with docosahexaenoic acid (DHA) and arachidonic acid (AA) - 0.5 mL oil (32 mg DHA and 31 mg AA) per 100 mL milk from 1 week after birth until discharge (9 weeks on average)
Number of subjects: 92
Study 20624152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no DHA and AA)
Number of subjects: 92
Study 19494788 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 1400 mg weekly on days 2, 9, and 16 plus Pemetrexed 500 mg/m every 21 days (arm A)
Number of subjects: 42
Study 19494788 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 250 mg on days 2 to 16 plus Pemetrexed 500 mg/m every 21 days (arm B)
Number of subjects: 42
Study 17765461 — intervention group
Group type: EXPERIMENTAL
Intervention: Early computed tomography (CT) examination
Number of subjects: 205
Study 17765461 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP) - supine abdominal and erect chest radiography
Number of subjects: 205
Study 17765461 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 205
Study 14742841 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1.2 g/d) and vitamin D (8 microg/d) supplementation for 6 months in RYGB women with low bone mass, n = 13
Number of subjects: 44
Study 14742841 — intervention group
Group type: COMPARATOR
Intervention: RYGB women
Number of subjects: 44
Study 14742841 — intervention group
Group type: COMPARATOR
Intervention: Control women (CNT), n = 65
Number of subjects: 44
Study 11387860 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 0
Study 11387860 — intervention group
Group type: EXPERIMENTAL
Intervention: Declaration of Helsinki
Number of subjects: 0
Study 11387860 — intervention group
Group type: EXPERIMENTAL
Intervention: Belmont Report
Number of subjects: 0
Study 11387860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical principle of fidelity
Number of subjects: 0
Study 9396449 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse durations (2, 3, 4, 6 ms)
Number of subjects: 29
Study 9396449 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulse durations (6, 12, 18 ms)
Number of subjects: 29
Study 9396449 — intervention group
Group type: EXPERIMENTAL
Intervention: Short and long pulse durations
Number of subjects: 29
Study 9396449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored energy at defibrillation threshold
Number of subjects: 29
Study 9396449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean current over the full range of pulse durations
Number of subjects: 29
Study 8126716 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prevention program
Number of subjects: 389
Study 8126716 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusal skills training
Number of subjects: 389
Study 2446081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg orally)
Number of subjects: 0
Study 2446081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg orally)
Number of subjects: 0
Study 2446081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (20 mg orally)
Number of subjects: 0
Study 2446081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2446081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 0
Study 2446081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0
Study 31426829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative CT scanning
Number of subjects: 0
Study 31426829 — intervention group
Group type: COMPARATOR
Intervention: No intra-operative CT scanning (Control)
Number of subjects: 0
Study 25970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-based programs (approximately $800 for smoking cessation)
Number of subjects: 2538
Study 25970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Deposit-based programs ($150 refundable deposit plus $650 in reward payments)
Number of subjects: 2538
Study 25970009 — intervention group
Group type: COMPARATOR
Intervention: Usual care (informational resources and free smoking-cessation aids)
Number of subjects: 2538
Study 25970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-oriented programs
Number of subjects: 2538
Study 25970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-oriented programs
Number of subjects: 2538
Study 25970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-based programs
Number of subjects: 2538
Study 25970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Deposit-based programs
Number of subjects: 2538
Study 23605170 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg) and folic acid (1 mg) per day for 2 months
Number of subjects: 359
Study 23605170 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (1 mg) per day for 2 months (Control)
Number of subjects: 359
Study 22084374 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 337
Study 22084374 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 337
Study 19620848 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX054 (50/200 mg) twice daily
Number of subjects: 12
Study 19620848 — intervention group
Group type: COMPARATOR
Intervention: CD/LD (25/100 mg) 4 times daily
Number of subjects: 12
Study 16836171 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) allograft
Number of subjects: 1
Study 16836171 — intervention group
Group type: COMPARATOR
Intervention: Palatal autograft
Number of subjects: 1
Study 12612511 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg midazolam plus 50 mg meperidine (Group B)
Number of subjects: 253
Study 12612511 — intervention group
Group type: COMPARATOR
Intervention: 5 mg midazolam and placebo (Group A)
Number of subjects: 253
Study 10852763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 400 microg
Number of subjects: 38
Study 10852763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8811136 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren), 50 mg two or three times a day
Number of subjects: 32
Study 8811136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1329231 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide administration (schedule not specified)
Number of subjects: 80
Study 1329231 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide with cisplatin (schedule not specified)
Number of subjects: 80
Study 1329231 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide without cisplatin (schedule not specified)
Number of subjects: 80
Study 6724125 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 200 mg tablets
Number of subjects: 0
Study 6724125 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 mg tablets
Number of subjects: 0
Study 29618121 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic bDMARDs treatment (ustekinumab, secukinumab, TNF inhibitors based on T cell phenotype)
Number of subjects: 64
Study 29618121 — intervention group
Group type: COMPARATOR
Intervention: Standard bDMARDs treatment
Number of subjects: 64
Study 29521922 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot exercises (daily for 12 weeks)
Number of subjects: 60
Study 29521922 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard wound care with foot exercises
Number of subjects: 60
Study 29521922 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard wound care only)
Number of subjects: 60
Study 25695485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1059
Study 25695485 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1059
Study 23726668 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 12 weeks
Number of subjects: 1116
Study 21346736 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 21346736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 0
Study 21346736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study 18766387 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐TCP (Cerasorb) in combination with PRP
Number of subjects: 22
Study 18766387 — intervention group
Group type: COMPARATOR
Intervention: beta‐TCP (Cerasorb) alone
Number of subjects: 22
Study 17207645 — intervention group
Group type: EXPERIMENTAL
Intervention: Degenerative meniscus tear (diagnosed by MRI)
Number of subjects: 41
Study 17207645 — intervention group
Group type: COMPARATOR
Intervention: No degenerative meniscus tear
Number of subjects: 41
Study 16739362 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberogast (3 x 20 drops daily for 4 weeks)
Number of subjects: 592
Study 16739362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 16739362 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (positive control)
Number of subjects: 592
Study 11321874 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF or GM-CSF
Number of subjects: 12
Study 11321874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8199081 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceed (absorbable adhesion barrier)
Number of subjects: 28
Study 8199081 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgery with hydrocortisone
Number of subjects: 28
Study 3444905 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine (150 mg t.i.d.) + radiotherapy (RT)
Number of subjects: 50
Study 3444905 — intervention group
Group type: COMPARATOR
Intervention: placebo (PLAC) + radiotherapy (RT)
Number of subjects: 50
Study 29409951 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab every 8 weeks
Number of subjects: 0
Study 29409951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28494910 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal presence during anesthesia induction
Number of subjects: 48
Study 28494910 — intervention group
Group type: COMPARATOR
Intervention: Separation from mothers during anesthesia induction
Number of subjects: 48
Study 26561632 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccenic acid (VA)
Number of subjects: 106
Study 26561632 — intervention group
Group type: EXPERIMENTAL
Intervention: Industrial trans fatty acids (iTFA)
Number of subjects: 106
Study 26561632 — intervention group
Group type: EXPERIMENTAL
Intervention: c9,t11-conjugated linoleic acid (c9,t11-CLA)
Number of subjects: 106
Study 26561632 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.1% mixed isomers of TFA)
Number of subjects: 106
Study 24009137 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine replacement therapy
Number of subjects: 20
Study 24009137 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy women)
Number of subjects: 20
Study 21262507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 178
Study 21262507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 18978623 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (1 x 20, 2 x 20, 3 x 20)
Number of subjects: 34
Study 18978623 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (1 x 20, 1 x 40) and PNF stretching
Number of subjects: 34
Study 18978623 — intervention group
Group type: COMPARATOR
Intervention: Low volume of static stretching
Number of subjects: 34
Study 16580290 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate (40 mg)
Number of subjects: 0
Study 16580290 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (2 mg)
Number of subjects: 0
Study 12680890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg x 4 for 3 days
Number of subjects: 36
Study 12680890 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg x 4 for 3 days
Number of subjects: 36
Study 10974183 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (cycling, walking, strength training)
Number of subjects: 100
Study 10974183 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 100
Study 9096920 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine RNVG
Number of subjects: 41
Study 9096920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine RNVG
Number of subjects: 41
Study 9096920 — intervention group
Group type: COMPARATOR
Intervention: Exercise RNVG
Number of subjects: 41
Study 8342751 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 8342751 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40
Study 8342751 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 40
Study 8342751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8342751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 40
Study 3555364 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 200
Study 3555364 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy and antrectomy (SV-A)
Number of subjects: 200
Study 31057139 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively-valenced Affective Six Elements Test (A-SET)
Number of subjects: 60
Study 31057139 — intervention group
Group type: COMPARATOR
Intervention: Positively-valenced Affective Six Elements Test (A-SET)
Number of subjects: 60
Study 30158057 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of loop diuretics
Number of subjects: 2004
Study 30158057 — intervention group
Group type: COMPARATOR
Intervention: Continuous use of loop diuretics
Number of subjects: 2004
Study 30158057 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation or discontinuation of diuretics
Number of subjects: 2004
Study 27647847 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery stenting plus optimal medical therapy
Number of subjects: 947
Study 27647847 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 947
Study 24721114 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiki (experimental intervention)
Number of subjects: 20
Study 24721114 — intervention group
Group type: COMPARATOR
Intervention: Discussion group (control intervention)
Number of subjects: 20
Study 24721114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Wiki and Discussion group)
Number of subjects: 20
Study 24721114 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations produced by participants
Number of subjects: 20
Study 23706520 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 20 weeks
Number of subjects: 120
Study 23706520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20530299 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict blood pressure control (<140 mm Hg)
Number of subjects: 3260
Study 20530299 — intervention group
Group type: COMPARATOR
Intervention: Moderate blood pressure control (>=140 mm Hg to <150 mm Hg)
Number of subjects: 3260
Study 18155609 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 0
Study 18155609 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS
Number of subjects: 0
Study 18155609 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 0
Study 18155609 — intervention group
Group type: EXPERIMENTAL
Intervention: MOMI
Number of subjects: 0
Study 18155609 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythema plus ulceration
Number of subjects: 0
Study 16157752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 12
Study 16157752 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 12
Study 16157752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 12
Study 16157752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise
Number of subjects: 12
Study 16157752 — intervention group
Group type: EXPERIMENTAL
Intervention: Second wind phenomenon
Number of subjects: 12
Study 12515740 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS stent (n=31)
Number of subjects: 61
Study 12515740 — intervention group
Group type: COMPARATOR
Intervention: Control stent (n=30)
Number of subjects: 61
Study 10664641 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote video technology in home health care setting
Number of subjects: 212
Study 10664641 — intervention group
Group type: COMPARATOR
Intervention: Routine home health care (control)
Number of subjects: 212
Study 8833507 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination of tooth surfaces
Number of subjects: 4294
Study 8833507 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar occlusal surfaces
Number of subjects: 4294
Study 8833507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure caries
Number of subjects: 4294
Study 8833507 — intervention group
Group type: EXPERIMENTAL
Intervention: Interproximal surfaces
Number of subjects: 4294
Study 8833507 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth surfaces
Number of subjects: 4294
Study 8833507 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year increments of caries
Number of subjects: 4294
Study 8305642 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR measurements using renal clearance of [125I]iothalamate after an sc injection without epinephrine.
Number of subjects: 2250
Study 2863920 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (AZ) 0.25 mg
Number of subjects: 24
Study 2863920 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 5 mg
Number of subjects: 24
Study 2863920 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (AZ) 0.75 mg
Number of subjects: 24
Study 31888551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with cisplatin plus 5-fluorouracil (NPF group)
Number of subjects: 118
Study 31888551 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel combined with cisplatin plus 5-fluorouracil (DPF group)
Number of subjects: 118
Study 29889923 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal sinus lift elevation using the CAS kit with grafting (anorganic bovine bone)
Number of subjects: 35
Study 29889923 — intervention group
Group type: COMPARATOR
Intervention: Crestal sinus lift elevation using the CAS kit without grafting
Number of subjects: 35
Study 27513584 — intervention group
Group type: EXPERIMENTAL
Intervention: EX/RP
Number of subjects: 0
Study 27513584 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 0
Study 24802974 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral Δ(9) -tetrahydrocannabinol (THC)
Number of subjects: 15
Study 24802974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23036785 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient diabetes management and education with improved transition to outpatient care (IDMET)
Number of subjects: 31
Study 23036785 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 31
Study 20689095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-CHO (3.6 kcal/kg, 0.36 g protein/kg)
Number of subjects: 18
Study 18573825 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta therapy
Number of subjects: 43
Study 18573825 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched volunteers)
Number of subjects: 43
Study 15818079 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's assessments of pain severity
Number of subjects: 66
Study 15818079 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's assessments of volume asymmetry
Number of subjects: 66
Study 15818079 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's assessments of temperature asymmetry
Number of subjects: 66
Study 15818079 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring changes in symptoms between assessments
Number of subjects: 66
Study 12809076 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (200 mg intramuscularly every 2 weeks)
Number of subjects: 36
Study 12809076 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 10589852 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental respiratory muscle training (RMT) with resistive inspiratory and expiratory loads for 6 months
Number of subjects: 21
Study 10589852 — intervention group
Group type: COMPARATOR
Intervention: No load training (NT)
Number of subjects: 21
Study 8758538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha Interferon therapy
Number of subjects: 0
Study 8758538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus natural alpha Interferon
Number of subjects: 0
Study 8758538 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexamethasone‐alpha Interferon
Number of subjects: 0
Study 8758538 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 8758538 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 1913091 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliofemoral bypass
Number of subjects: 74
Study 1913091 — intervention group
Group type: COMPARATOR
Intervention: Femorofemoral bypass
Number of subjects: 74
Study 6837688 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 32
Study 6837688 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 31654784 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT 30 Gy/10 fractions
Number of subjects: 194
Study 31654784 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT 37.5 Gy/15 fractions
Number of subjects: 194
Study 29980851 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (0.33 g·kg BM‐1)
Number of subjects: 8
Study 29980851 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (0.33 g·kg BM‐1) with prior aerobic exercise
Number of subjects: 8